BIOmarker

Type:
Studiedocumentatie
Ziektebeelden:
Leeftijd:
≥ 18 jr
Fase:
N.v.t.
Lijn:
N.v.t.
Status:
Open
Locatie:
Amsterdam UMC
Volledige titel Characterization of buffy-coat-derived granulocytes for clinical use: - identifying clinical and laboratory parameters for decision making A pilot study
Documenten

 
Samenvatting met in- en exclusiecriteria

Overall aim
The overall aim of this pilot study is to assess which markers are present in patients eligible for GTX. Also,
the number of eligible patients will be assessed. The outcomes can be used to set up a large (multicentre)
trial to assess biomarkers for GTX indication in the future. This might make GTX more effective and makes it
possible to study GTX safety and efficacy.
Markers will also be analysed in their value reflecting the cause and course of the neutropenic fever.

 

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

  • 18 years or older
  • Admitted to the adult haematology department of the AMC
  • Receiving intensive chemotherapy for acute myeloid leukemia or autologous hematopoietic stem cell
    transplantation.
  • Able and willing to provide written and dated informed consent prior to any study specific procedure

Veiligheidsinformatie
Emergency contact

nvt
Niet geregistreerde geneesmiddelen

nvt
Geregistreerde geneesmiddelen

nvt
Naam contactpersoon Medical Monitor nvt
Hoe Medical Monitor te bereiken nvt
NB
Principal investigator Amsterdam UMC nvt
Principal investigator elders Erfan Nur
Aanmelden van patiënten AMC Aanmelden van patiënten bij trialbureau hematologie (sein 29255, hemat.trial@amc.nl)
Aanmelden van patiënten VUmc nvt